Megan Kinzel

A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin.

J. Storek, A. Kalra, F. Khan, 2021, Cytotherapy.

Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host disease.

J. Storek, P. Duggan, V. Jimenez-Zepeda, 2022, Cytotherapy.

Risk factors for the incidence of PTLD and the mortality due to PTLD after hematopoietic cell transplantation.

J. Storek, P. Duggan, V. Jimenez-Zepeda, 2021, Transplantation and cellular therapy.

Rituximab toxicity after preemptive or therapeutic administration for post-transplant lymphoproliferative disorder.

J. Storek, P. Duggan, A. Kalra, 2022, Transplantation and cellular therapy.

Lack of both donor and recipient anti-EBV T cells in EBV seronegative recipients of grafts from seropositive donors

J. Storek, A. Kalra, G. Tripathi, 2022, Bone Marrow Transplantation.

Targeting Potential of Innate Lymphoid Cells in Melanoma and Other Cancers

Qiutong Huang, D. Mahoney, N. Jacquelot, 2023, Pharmaceutics.